

Supplementary Table S2. Effectiveness of dabrafenib combined with trametinib by the line of therapy in which it was received

	Total^a	First line	≥ Second line
Observed population	<i>N</i> = 271	<i>n</i> = 171	<i>n</i> = 80
Median PFS (95% CI), months	6.8 (6.2–8.1)	8.1 (6.6–10)	5 (3.9–6.3)
Median OS (95% CI), months	18.4 (15.1–NR)	20 (15.5–NR)	15.1 (8.7–NR)
Best overall response, <i>n</i> (%) (95% CI) ^b			
Overall response rate ^c	172 (63.5) (57.4–69.2)	112 (65.5) (57.9–72.6)	48 (60.0) (48.4–70.8)
Complete response	47 (17.3)	28 (16.4)	14 (17.5)
Partial response	125 (46.1)	84 (49.1)	34 (42.5)
Stable disease	33 (12.2)	24 (14.0)	7 (8.8)
Progressive disease	58 (22.4)	28 (16.4)	25 (31.3)
BRAF inhibitor-naive population	<i>n</i> = 162 ^b	<i>n</i> = 140	<i>n</i> = 22
Median PFS (95% CI), months		8.0 (6.2–9.5)	7.1 (4.6–11.4)
Median OS (95% CI), months		20.0 (14.7–NR)	15.1 (8.7–NR)
Best overall response, <i>n</i> (%) ^c			
Overall response rate ^d		93 (66.4)	16 (72.7)
Complete response		18 (12.9)	3 (13.6)
Partial response		75 (53.6)	13 (59.1)
Stable disease		18 (12.9)	2 (9.1)
Progressive disease		23 (16.4)	4 (18.2)

CI, confidence interval; NR, not reached; OS, overall survival; PFS, progression-free survival.

^aData missing for 8 patients in the observed population and 6 patients in the BRAF inhibitor-naive population.

^bData for the total BRAF inhibitor-naive population can be found in the primary manuscript (Table 2).

^cBest overall response was unknown for 8 patients, 7 of whom received dabrafenib plus trametinib as first-line therapy.

^dComplete response + partial response.